Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Notes Payables Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Intelligent Bio Solutions (INBS) Non-Current Deffered Revenue (2021 - 2022)

Intelligent Bio Solutions has reported Non-Current Deffered Revenue over the past 2 years, most recently at $1.6 million for Q4 2022.

For Q4 2022, Non-Current Deffered Revenue rose 35.39% year-over-year to $1.6 million; the TTM value through Dec 2022 reached $1.6 million, up 35.39%, while the annual FY2022 figure was $1.1 million, 65.29% down from the prior year.
Non-Current Deffered Revenue for Q4 2022 was $1.6 million at Intelligent Bio Solutions, down from $2.6 million in the prior quarter.
Over five years, Non-Current Deffered Revenue peaked at $3.1 million in Q2 2021 and troughed at $1.1 million in Q2 2022.